Study To Assess Long Term Safety Of Pazopanib

• Status: Completed
• Trial end date: 2018-03-08
• Target enrollment: 0
• Participant gender: All

Summary

This study was a rollover study to evaluate the long term safety of pazopanib and to continue to provide pazopanib to patients who participated in a GSK sponsored pazopanib study until pazopanib is available commercially.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Lapatinib

Criteria

Key Inclusion Criteria:

• Participated or completed a GSK sponsored pazopanib study and remains eligible for continued treatment with pazopanib and lapatinib (if on combination therapy).

• Able to understand and provide written informed consent

• Women and men agree to use protocol specific birth control measures

Key Exclusion Criteria:

• The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer

• If you are pregnant or breast feeding

• Your doctor does not think you would be a good candidate for the study

• Poorly controlled high blood pressure

• Subject is unwilling or unable to follow the procedures outlined in the protocol.